

Medikamenten-assoziierte Kiefernekrose – Herausforderung in der zahnärztlichen Praxis

Dr. med. Dr. med. dent. Susanne Jung, MHBA, LL. M.

Literatur

- [1] AAOMS. American Association of Oral and Maxillofacial Surgeons: Position Paper on Bisphosphonate Related Osteonecrosis of the Jaws - 2009 Update. *J Oral Maxillofac Surg* 2009 May; 67(5 Suppl):2-12.
- [2] Baron R, Ferrari S, Russel RG. Denosumab and bisphosphonates: different mechanisms of action and effects. *Bone*. 2011;48:677-92.
- [3] Bartl R, von Tresckow E, Bartl C. *Bisphosphonat-Manual* (2006). Springer Verlag, Berlin New York Heidelberg 2006. ISBN 3-540-25362-9.
- [4] Epstein MS, Ephros HD, Epstein JB. Review of current literature and implications of RANKL inhibitors for oral health care providers. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2013 Dec;116(6):e437-42. doi: 10.1016/j.oooo.2012.01.046. Epub 2012 Aug 15.
- [5] Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration resistant prostate cancer: a randomised, double-blind study. *Lancet*, 2011. 377(9768):813-22.
- [6] Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2012 Jan 2.
- [7] Grötz KA, Piesold J-U, Al-Nawas B. Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. S3 Leitlinie. Stand: 4/12. AWMF online, Register Nr. 007/91. http://www.awmf.org/upload/tx_szleitlinien/007-091I_S3_Bisphosphonat-assoziierte_Kiefernekrose_2012-verlaengert.pdf, Abruf 31.08.2015
- [8] Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. *Breast Cancer Res Treat*, 2010. 122(1):181-8.
- [9] Hopp RN, Pucci J, Santos-Silva AR, Jorge J. Osteonecrosis after administration of intravitreal bevacizumab. *J Oral Maxillofac Surg*. 2012;70(3):632-5. Epub 2011 Jul 14.

- [10] Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. *J Dent Res*. 2015 Apr;94(4):534-9. doi: 10.1177/0022034515572021. Epub 2015 Feb 20.
- [11] Kyrgidis A, Toulis KA. Denosumab-related osteonecrosis of the jaws. *Osteoporos Int* 2011;22:369-70.
- [12] Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study. *Implant Dent*, 2010. 19(1):29-38.
- [13] Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg* 2003; 61(9):1115-1117.
- [14] McLeod NM, Patel V, Kusanale A, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw: a literature review of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. *Br J Oral Maxillofac Surg*. 2011 Jul;49(5):335-42. doi: 10.1016/j.bjoms.2010.08.005. Epub 2010 Sep 22.
- [15] O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator. *J Oral Maxillofac Surg*, 2009. 67(7):1363-72.
- [16] Pautke C, Bauer F, Tischer T, Kreutzer K, Weitz J, Kesting M. Fluorescence-guided bone resection in bisphosphonate-associated osteonecrosis of the jaws. *J Oral Maxillofac Surg* 2009;67:471-6.
- [17] Rote-Hand-Brief, Amgen,
<http://www.akdae.de/Arzneimittelsicherheit/RHB/20150729.pdf>
Abruf: 30.08.2015
- [18] Rote-Hand-Brief, Roche,
<http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2010/201011301.pdf>
Abruf: 30.08.2015
- [19] Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): ^ initial discovery and subsequent development. *J Oral Maxillofac Surg* 2009;67(5 Suppl):13-18.
- [20] Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. *Aust Endod J*. 2009 Dec;35(3):119-30.
- [21] Saccardin F, Filippi A, Kühl S. Antiresorptive Medikamente: Oralmedizinische Konsequenzen und Therapieansätze bei Osteonekrosen des Kiefers, *Quintessenz* 2015;66(6):691-700.

- [22] Santos-Silva AR, Belizário Rosa GA, Castro Júnior Gd, Dias RB, Prado Ribeiro AC, Brandão TB. Osteonecrosis of the mandible associated with bevacizumab therapy. *Oral Surg Oral Med Oral Pathol Oral Radiol*. 2013 Jun;115(6):e32-6. doi: 10.1016/j.oooo.2013.02.001. Epub 2013 Apr 6.
- [23] Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. *J Clin Oncol*. 2010 Dec 10;28(35):5132-9.
- [24] Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. *J Oral Maxillofac Surg* 2003; 61(9):1104-1107.